Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy

Core Insights - Apellis Pharmaceuticals Inc. is highlighted as a promising investment opportunity due to the positive long-term benefits of its drug SYFOVRE for treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD) [1][3] Group 1: Drug Efficacy and Study Results - A post hoc analysis of the Phase 3 GALE extension study indicates that SYFOVRE can delay GA lesion growth by approximately 1.5 years with both monthly and bi-monthly administration compared to sham treatment [2][3] - SYFOVRE is the first FDA-approved therapy for geographic atrophy, targeting C3 to control the complement cascade effectively [3] Group 2: Disease Impact - Geographic atrophy is a progressive and irreversible disease that leads to blindness, affecting over 1 million Americans and 5 million people globally [2]